6/23T9:14 Co. in the News

Companies in the News:

MYGN Myriad Genetics: Bapineuzumab not necessarily a positive signal for Flurizan - Cowen (50.37 )
Cowen says top-line results from the Flurizan U.S. Phase III Alzheimer's trial are expected to be released this week. With MYGN shares up 10% since the release of the bapineuzumab top-line Phase II results, they believe investors now are more optimistic about Flurizan's chances for success. Firm's analysis of the available clinical and pre-clinical data and checks with their clinical and statistical consultants lead them to conclude that the Phase III trial may show a positive treatment trend, but Flurizan is unlikely to achieve statistically significant efficacy. While MYGN shares could have as much as 30% upside potential should the Flurizan Phase III program succeed, firm believes that is a very low probability (<20%) outcome.